Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Variants & evidence
382 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| SSX1 Fusion6 | ||||||||
| (diagnostic) | Synovial Sarcoma | Diagnostic | B | Supports Positive | 4 | accepted | EID1069In this review, the author summarize the role of this fusion in diagnosis of synovial sarcomas. Cytogenetic studies have repeatedly demonstrated the t(X;18)(p11;q11) translocation in approximately 90%… (full text at CIViC) PMID 11122430 · Pfeifer et al., 2000 · Open in CIViC | civic |
| 〃 | Synovial Sarcoma | Diagnostic | B | Supports Positive | 4 | accepted | EID1070In this study, 141 spindle cell sarcomas were evaluated for the presence of t(X;18) by RT-PCR. 85% of the synovial sarcomas were positive for this event. The study did not indicate the specific fusion… (full text at CIViC) PMID 11144931 · O'Sullivan et al., 2000 · Open in CIViC | civic |
| (prognostic) | Synovial Sarcoma | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1072This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-… (full text at CIViC) PMID 11782370 · Ladanyi et al., 2002 · Open in CIViC | civic |
| (diagnostic) | Synovial Sarcoma | Diagnostic | B | Supports Positive | 4 | accepted | EID12122This study used RT-PCR assays to screen tumor blocks for SS18::SSX1 fusion transcripts in 134 synovial sarcomas cases. 194 normal tissue and samples from unrelated tumor types were used as negative co… (full text at CIViC) PMID 17334349 · Amary et al., 2007 · Open in CIViC | civic |
| 〃 | Synovial Sarcoma | Diagnostic | B | Supports Positive | 3 | accepted | EID1065A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as … (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC | civic |
| (prognostic) | Synovial Sarcoma | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1068In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologi… (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC | civic |
| SSX2 Fusion4 | ||||||||
| (diagnostic) | Synovial Sarcoma | Diagnostic | A | Supports Positive | 4 | accepted | EID1064A t(X;18) is detected cytogenetically in over 90% of synovial sarcomas, regardless of histologic subtype. This translocation results primarily in two fusions. SYT-SSX1 (aka SS18-SSX1) and SYT-SSX2 (ak… (full text at CIViC) PMID 11607825 · Ladanyi, 2001 · Open in CIViC | civic |
| 〃 | Synovial Sarcoma | Diagnostic | B | Supports Positive | 3 | accepted | EID1066A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. SYT (aka SS18) pairs with various 3' partners know as … (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC | civic |
| (prognostic) | Synovial Sarcoma | Prognostic | B | Supports Better Outcome | 3 | accepted | ||
| SSX4 Fusion1 | ||||||||
| (diagnostic) | Synovial Sarcoma | Diagnostic | C | Supports Positive | 2 | accepted | EID1074Three synovial sarcomas were assayed for SYT-SSX fusion messenger RNA by nested RT-PCR. In a single case an SYT-SSX4 (SS18-SSX4) fusion was detected. The majority of synovial sarcomas are characterize… (full text at CIViC) PMID 10359553 · Skytting et al., 1999 · Open in CIViC | civic |
| ROS1 Fusion3 | ||||||||
| Crizotinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID1444Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-R… (full text at CIViC) PMID 24875859 · Lovly et al., 2014 · Open in CIViC | civic |
| Entrectinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID11860In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with inflammat… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| 〃 | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | ||||
| ALK Fusion1 | ||||||||
| Lorlatinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11293This case study was on a 40-year-old male with dyspnea and a productive cough. He was found to have a right upper lobe opacity on a chest X-ray. Subsequent investigations, including CT and PET, showed… (full text at CIViC) PMID 32868646 · Wong et al., 2020 · Open in CIViC | civic |
| NTRK1 Fusion1 | ||||||||
| (oncogenic) | NTRK-Rearranged Spindle Cell NeoplasmALIAS | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID11704An intra-chromosomal TPR::NTRK1 fusion was found in a superficial soft tissue tumor located on the hand of a 7-year-old girl. The tumor had a prominently infiltrative growth pattern reminiscent of lip… (full text at CIViC) PMID 27259011 · Agaram et al., 2016 · Open in CIViC | civic |
| ALK Fusion9 | ||||||||
| (diagnostic) | Inflammatory Myofibroblastic Tumor | Diagnostic | C | Supports Positive | 4 | accepted | EID1783Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT. PMID 10383129 · Griffin et al., 1999 · Open in CIViC | civic |
| Brigatinib | Inflammatory Myofibroblastic Tumor | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID11290In this single-arm, open-label, phase 1/2 trial 137 patients who had advanced malignancies, including ALK-rearranged NSCLC and two patients with inflammatory myofibroblastic tumour (IMT) were enrolled… (full text at CIViC) PMID 27836716 · Gettinger et al., 2016 · Open in CIViC | civic |
| Ceritinib | Inflammatory Myofibroblastic Tumor | Predictive | B | Supports Sensitivity Response | 3 | submitted | ||
| NTRK1 Fusion1 | ||||||||
| (diagnostic) | NTRK-Rearranged Spindle Cell NeoplasmALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID7293Among pediatric fibroblastic and myofibroblastic proliferating superficial lesions, lipofibromatosis (LPF), composed of an admixture of adipose tissue and fibroblastic elements, has been variously cla… (full text at CIViC) PMID 27259011 · Agaram et al., 2016 · Open in CIViC | civic |
| TFE3 Fusion3 | ||||||||
| (diagnostic) | PEComaALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID11606In this study, the authors evaluated 60 Xp11 translocation neoplasms, including 8 perivascular epithelioid cell tumors (PEComas), to characterize the diagnostic significance of TFE3 fusion variants. U… (full text at CIViC) PMID 26975036 · Argani et al., 2016 · Open in CIViC | civic |
| 〃 | PEComaALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID12690In this study the authors examined six gynecologic tract perivascular epithelioid cell tumors (PEComas) that were previously diagnosed as PEComa but demonstrated unusual morphology suggestive of TFE3 … (full text at CIViC) PMID 25517951 · Schoolmeester et al., 2015 · Open in CIViC | civic |
| 〃 | PEComaALIAS | Diagnostic | ||||||
| NUTM2A Fusion + NUTM2B Fusion + NUTM2E FusionNUTM2ANUTM2BNUTM2E3 | ||||||||
| (diagnostic) | Clear Cell Sarcoma of the KidneyALIAS | Diagnostic | B | Supports Positive | 3 | accepted | EID11782In this 2012 study O’Meara et al. included 51 clear cell sarcoma of kidney (CCSK). Using an index CCSK with the t(10;17)(q22;p13) identified by cytogenetics, they were able to map the breakpoints and … (full text at CIViC) PMID 22294382 · O'Meara et al., 2012 · Open in CIViC | civic |
| 〃 | Clear Cell Sarcoma of the KidneyALIAS | Diagnostic | C | Supports Positive | 2 | accepted | EID11783In this 2020 study Kenny et al. included 68 cases of clear cell sarcoma of the kidney (CCSK). Using RT-PCR with RNA extracted from FFPE tumour tissue they detected a YWHAE::NUTM2 fusion transcript in… (full text at CIViC) PMID 32364435 · Kenny et al., 2020 · Open in CIViC | |
Data updated 12 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
EID1067In this study, SYT-SSX fusion transcripts (SS18-SSX1 and SS18-SSX2) were detected in 29 (64%) and 16 (36%) of the tumors, respectively. There was a significant relationship (P=0.003) between histologi… (full text at CIViC) PMID 9428816 · Kawai et al., 1998 · Open in CIViC |
| civic |
| 〃 | Synovial Sarcoma | Prognostic | B | Supports Better Outcome | 3 | accepted | EID1073This study collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6-82) with synovial sarcoma. SYT-SSX1 and SYT-… (full text at CIViC) PMID 11782370 · Ladanyi et al., 2002 · Open in CIViC | civic |
| 1 |
| accepted |
EID11862In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with myofibrob… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC |
| civic |
EID11291In this phase 1 study, oral ceritinib was administered to 59 patients in doses of 50 - 750 mg once daily to patients with advanced cancers harbouring genetic alterations in ALK. A total of 130 patient… (full text at CIViC) PMID 24670165 · Shaw et al., 2014 · Open in CIViC |
| civic |
| 〃 | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7547In a phase I study of the efficacy of ceritinib in ALK fusion positive cancer, a single patient with inflammatory myofibroblastic tumor was treated with 750mg daily ceritinb and showed a partial respo… (full text at CIViC) PMID 24670165 · Shaw et al., 2014 · Open in CIViC | civic |
| Crizotinib | Inflammatory Myofibroblastic Tumor | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID111229 patients with ALK-positive inflammatory myofibroblastic tumour (IMT) enrolled in the PROFILE 1013 (NCT01121588) phase 1b single-arm, open-label, multi-centre study received crizotinib. ORR was 67% f… (full text at CIViC) PMID 29352732 · Gambacorti-Passerini et al., 2018 · Open in CIViC | civic |
| 〃 | Inflammatory Myofibroblastic Tumor | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1243As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |
| 〃 | Inflammatory Myofibroblastic Tumor | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID7362In this phase I/II study, 14 patients with metastatic or inoperable ALK-positive IMT were administered crizotinib orally twice daily in 28-day cycles as a single agent for an indefinite duration. The … (full text at CIViC) PMID 28787259 · Mossé et al., 2017 · Open in CIViC | civic |
| 〃 | Vaginal SarcomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID6042Patient was 34-year-old woman with vaginal sarcoma, which was excised with positive surgical margins. Fluorescence in situ hybridization testing of her tumor revealed anaplastic lymphoma kinase gene … (full text at CIViC) PMID 26942346 · Forde et al., 2016 · Open in CIViC | civic |
| Lorlatinib | Inflammatory Myofibroblastic Tumor | Predictive | C | Supports Sensitivity Response | 4 | submitted | EID11294This case study was on an 18-year-old Caucasian female presenting with severe headaches. Brain MRI revealed multiple brain masses with the largest (5 cm) found in the anterior left frontal lobe. A met… (full text at CIViC) PMID 28713152 · Yuan et al., 2017 · Open in CIViC | civic |
| B |
| Supports Positive |
| 3 |
| accepted |
EID12691In this 2025 study, the authors included 14 confirmed TFE3-rearranged perivascular epithelioid cell tumors (PEComas), previously classified as benign (9 tumors) or malignant (5 tumors), and compared t… (full text at CIViC) PMID 40462401 · Papke et al., 2025 · Open in CIViC |
| civic |
| civic |
| 〃 | Clear Cell Sarcoma of the KidneyALIAS | Diagnostic | C | Supports Positive | 2 | accepted | EID11784In this 2016 study Kenny et al. included 159 cases of clear cell sarcoma of the kidney (CCSK). RNA was extracted from either snap-frozen or FFPE tumour tissue samples and real-time PCR used to identif… (full text at CIViC) PMID 27000436 · Kenny et al., 2016 · Open in CIViC | civic |